高龄患者腹主动脉瘤修复术后的围手术期死亡率和生存率:挪威血管外科登记处聚焦九十岁以上患者的全国性研究
该全国性观察队列研究纳入挪威血管外科登记处2015至2021年所有腹主动脉瘤修复术患者,分为90岁以上组(n=77)、80至89岁组(n=1 362)和80岁以下组(n=4 590)。90岁以上患者中无症状者30天死亡率为2.5%,症状性为33.3%,破裂性为59.1%;无症状者估计中位生存3.3年。结论支持对经过选择的无症状90岁以上患者进行治疗,EVAR是首选方法。
要点
- 90岁以上无症状腹主动脉瘤患者30天死亡率为2.5%,症状性为33.3%,破裂性为59.1%。
- 90岁以上无症状患者估计中位生存3.3年,存活过90天者估计中位生存4.2年。
- 开放手术修复后90天死亡率无症状100.0%、症状性80.0%、破裂性62.5%;EVAR后分别为5.1%、10.0%、50.0%。
核心结论
- 90岁以上患者腹主动脉瘤术后的围手术期死亡率和生存结果支持对经过选择的无症状患者进行治疗。
- 存活过90天的患者预期生存超过三年,有助于在该具有挑战性的队列中平衡手术与保守治疗决策。
- EVAR是90岁以上患者腹主动脉瘤的首选治疗方法,因为大多数患者不治疗可能比开放手术修复生存更久。
研究设计与样本
- 挪威血管外科登记处2015至2021年所有腹主动脉瘤修复术的全国性观察队列研究。
- 患者分为90岁以上组(n=77)、80至89岁组(n=1 362)和80岁以下组(n=4 590)。
- 记录患者特征和合并症,计算30天和90天死亡率,采用Kaplan-Meier分析估计中位生存和生存曲线。
主要发现
- 90岁以上患者30天死亡率:无症状2.5%,症状性33.3%,破裂性腹主动脉瘤59.1%。
- 90岁以上患者估计中位生存:无症状3.3年(95%CI 1.95-4.59),症状性2.9年(IQR 2.82, 5.80),破裂性0.1年(IQR 0.01, 3.04)。
- 90岁以上存活过90天者估计中位生存:无症状4.2年(95%CI 2.56-5.88),症状性3.4年(IQR 2.86, 5.80),破裂性3.8年(IQR 1.49, 4.85)。
- 开放手术修复后90天死亡率:无症状100.0%,症状性80.0%,破裂性62.5%。
- EVAR后90天死亡率:无症状5.1%,症状性10.0%,破裂性50.0%。
临床怎么用
- 作者认为围手术期死亡率和生存结果支持对经过选择的90岁以上无症状患者进行治疗。
- 作者认为EVAR是90岁以上患者腹主动脉瘤的首选治疗方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Treatment of abdominal aortic aneurysm (AAA) in nonagenarians has become more frequent. This national observational cohort study aimed to investigate peri-operative mortality and survival after AAA surgery in nonagenarians in Norway. METHODS: All AAA repairs registered in the Norwegian Registry for Vascular Surgery from 2015 to 2021 were identified and stratified into nonagenarians > 90 years old (n = 77), octogenarians 80 - 89 years old (n = 1 362), and patients < 80 years old (n = 4 590). The patient characteristics and comorbidities were recorded, and the 30 and 90 day mortality rates were calculated. Kaplan-Meier analysis was performed to obtain the estimated median survival and survival curves. RESULTS: In the nonagenarians, the 30 day mortality rates were 2.5% in asymptomatic patients, 33.3% in symptomatic patients, and 59.1% in the patients with a ruptured AAA (rAAA). The estimated median survival (years) were 3.3 (95% confidence interval [CI] 1.95 - 4.59) for asymptomatic AAA, 2.9 (interquartile range [IQR] 2.82, 5.80) for symptomatic AAA, and 0.1 for rAAA (IQR 0.01, 3.04). For nonagenarians surviving the first 90 days, the estimated median survival (years) were 4.2 (95% CI 2.56 - 5.88) for asymptomatic AAA, 3.4 (IQR 2.86, 5.80) for symptomatic AAA, and 3.8 (IQR 1.49, 4.85) for rAAA. The 90 day mortality rates were 100.0%, 80.0%, and 62.5% for asymptomatic, symptomatic, and rAAA, respectively, after open surgical repair (OSR), and 5.1%, 10.0%, and 50.0%, respectively, after endovascular aortic repair (EVAR). CONCLUSION: Peri-operative mortality and survival results after AAA surgery in nonagenarians support treatment of selected asymptomatic patients. The 90 day survivors had an expected survival of more than three years, enabling balanced decision making regarding surgical vs. conservative treatment options in this challenging cohort. EVAR is the treatment method of choice for AAA in nonagenarians because most of them would probably live longer untreated than if treated by OSR.
引用
- Vikan KK, Seternes A, Nilsen LH, et al. Peri-Operative Mortality and Survival After Repair of Abdominal Aortic Aneurysm in Advanced Age Patients: A National Study from the Norwegian Registry for Vascular Surgery Focused on Nonagenarians. Eur J Vasc Endovasc Surg. 2023. PMID: 37778499. doi:10.1016/j.ejvs.2023.09.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。